Rupal Dhariwal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rupal Dhariwal has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Meenakshi Sharma
2 shared publications- Mukul Jain
Research and Development Cell, Parul University, Vadodara, India
2 shared publications - Nil Patil
Department of Life Sciences, Parul Institute of Applied Sciences, Parul University, Vadodara 391760, Gujarat, India
2 shared publications - Prashant Kaushik
Nagano University, 1088 Komaki, Ueda, Nagano 386-0031, Japan
2 shared publications Alpa Yadav
1 shared publication- Alpa Yadav
Department of Chemistry, Ranchi University, Ranchi 834001, India
1 shared publication
Latest Publications
- Open Access
- 24 September 2024
- Published by Elsevier in South African Journal of Botany
- Vol. 174, 551-559
Decoding eggplant fruit: Multi-omics profiling of caffeoyl-CoA-3-OMT expression
- 24 September 2024
- Published by Elsevier in South African Journal of Botany
- Vol. 174, 551-559
Open AccessDecoding eggplant fruit: Multi-omics profiling of caffeoyl-CoA-3-OMT expression
- 21 January 2024
- Published by Elsevier in Biocatalysis and Agricultural Biotechnology
- Vol. 56
Insilico and invitro profiling of curcumin and its derivatives as a potent acetylcholinesterase inhibitor
- 21 January 2024
- Published by Elsevier in Biocatalysis and Agricultural Biotechnology
- Vol. 56
Insilico and invitro profiling of curcumin and its derivatives as a potent acetylcholinesterase inhibitor
- Open Access
Unveiling the Molecular Footprint: Proteome-Based Biomarkers for Alzheimer’s Disease
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder characterized by progressive cognitive decline and memory loss. Early and accurate diagnosis of AD is crucial for implementing timely interventions and developing effective therapeutic strategies. Proteome-based biomarkers have emerged as promising tools for AD diagnosis and prognosis due to their ability to reflect disease-specific molecular alterations. There is of great significance for biomarkers in AD diagnosis and management. It emphasizes the limitations of existing diagnostic approaches and the need for reliable and accessible biomarkers. Proteomics, a field that comprehensively analyzes the entire protein complement of cells, tissues, or bio fluids, is presented as a powerful tool for identifying AD biomarkers. There is a diverse range of proteomic approaches employed in AD research, including mass spectrometry, two-dimensional gel electrophoresis, and protein microarrays. The challenges associated with identifying reliable biomarkers, such as sample heterogeneity and the dynamic nature of the disease. There are well-known proteins implicated in AD pathogenesis, such as amyloid-beta peptides, tau protein, Apo lipoprotein E, and clusterin, as well as inflammatory markers and complement proteins. Validation and clinical utility of proteome-based biomarkers are addressing the challenges involved in validation studies and the diagnostic accuracy of these biomarkers. There is great potential in monitoring disease progression and response to treatment, thereby aiding in personalized medicine approaches for AD patients. There is a great role for bioinformatics and data analysis in proteomics for AD biomarker research and the importance of data preprocessing, statistical analysis, pathway analysis, and integration of multi-omics data for a comprehensive understanding of AD pathophysiology. In conclusion, proteome-based biomarkers hold great promise in the field of AD research. They provide valuable insights into disease mechanisms, aid in early diagnosis, and facilitate personalized treatment strategies. However, further research and validation studies are necessary to harness the full potential of proteome-based biomarkers in clinical practice.
Open AccessUnveiling the Molecular Footprint: Proteome-Based Biomarkers for Alzheimer’s Disease
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder characterized by progressive cognitive decline and memory loss. Early and accurate diagnosis of AD is crucial for implementing timely interventions and developing effective therapeutic strategies. Proteome-based biomarkers have emerged as promising tools for AD diagnosis and prognosis due to their ability to reflect disease-specific molecular alterations. There is of great significance for biomarkers in AD diagnosis and management. It emphasizes the limitations of existing diagnostic approaches and the need for reliable and accessible biomarkers. Proteomics, a field that comprehensively analyzes the entire protein complement of cells, tissues, or bio fluids, is presented as a powerful tool for identifying AD biomarkers. There is a diverse range of proteomic approaches employed in AD research, including mass spectrometry, two-dimensional gel electrophoresis, and protein microarrays. The challenges associated with identifying reliable biomarkers, such as sample heterogeneity and the dynamic nature of the disease. There are well-known proteins implicated in AD pathogenesis, such as amyloid-beta peptides, tau protein, Apo lipoprotein E, and clusterin, as well as inflammatory markers and complement proteins. Validation and clinical utility of proteome-based biomarkers are addressing the challenges involved in validation studies and the diagnostic accuracy of these biomarkers. There is great potential in monitoring disease progression and response to treatment, thereby aiding in personalized medicine approaches for AD patients. There is a great role for bioinformatics and data analysis in proteomics for AD biomarker research and the importance of data preprocessing, statistical analysis, pathway analysis, and integration of multi-omics data for a comprehensive understanding of AD pathophysiology. In conclusion, proteome-based biomarkers hold great promise in the field of AD research. They provide valuable insights into disease mechanisms, aid in early diagnosis, and facilitate personalized treatment strategies. However, further research and validation studies are necessary to harness the full potential of proteome-based biomarkers in clinical practice.